I LOVE vinpocetine!!!
It make you smarter, stronger, harder, walk a lot better and piss like a "fire-hose"
VINPOCETINE HELPS MS PATIENTS
Exciting research with vinpocetine has been conducted on patients with multiple sclerosis. MS is a disease in which neural signals from the brain to the target muscle groups are obstructed because sclerotic plaques form in multiple locations along the nerve fibers and interrupt the signal transmission. As a result, the muscles weaken, and MS patients are often tired. In the later stages of the disease, they are often unable to walk, and they lose other motor skills as well.
MS patients treated with phosphodiesterase inhibitors, or PDEIs (see the sidebar for a description of phosphodiesterases and their inhibitors), exhibit a dramatic decrease in relapse rate.5 In a study published in the journal Multiple Sclerosis, 12 patients were treated with a cocktail of three different PDEIs, including 15 mg/day of vinpocetine, for an average of 499 days (1.4 years). The other two ingredients were the anti-Alzheimer's drug propentofylline and the antiasthma drug theophylline.
"Vinpocetine has the most clinical
promise for the management of
involving the brain."
Before the treatment, the patients averaged 3.1 relapses per year. During the treatment period, however, the incidence of relapses was much lower: only 0.92 per year. Seven of the 12 patients reported no relapses during the treatment period, three had a decreased incidence of relapses, and two had the same incidence as before. Since there were two other ingredients in the treatment formula, one can't say that vinpocetine alone was responsible for these results, but it likely played an important role in reducing the patients' relapse rates.
I hate to say this but Vinpocetine is a Potassium channel blocker.
That is what 4-AP does it should help MS folks walk better.
1: Neurosci Behav Physiol. 1998 Mar-Apr;28(2):116-20.Links
Nootropic agent vinpocetine blocks delayed rectified potassium currents more strongly than high-threshold calcium currents.Bukanova YuV , Solntseva EI.
Science Research Institute of the Brain, Russian Academy, Medical Sciences, Moscow.
A two-microelectrode potential clamping method was used on isolated common snail neurons to measure high-threshold Ca2+ and delayed rectified K+ currents. Addition of the nootropic agent vinpocetine (VPC) to the bathing solution rapidly and reversibly inhibited both types of current. The effects of VPC were dose-dependent and were independent of the test stimulus voltage. Maximum blockade of the Ca2+ current averaged 27% at a VPC concentration of 600 microM. Maximum blockade of the K+ current averaged 76% at a VPC concentration of 30 microM. It is concluded that K+ channels are more likely targets of VPC than Ca2+ channels.
PMID: 9604212 [PubMed - indexed for MEDLINE]
It also help with the MS urination problm.
1: World J Urol 2001 Nov;19(5):344-50
Phosphodiesterase 1 inhibition in the treatment of lower urinary tract
dysfunction: from bench to bedside.
Truss MC, Stief CG, Uckert S, Becker AJ, Wefer J, Schultheiss D, Jonas U.
Urologische Klinik, Medizinische Hochschule, Hannover, Germany.
Anticholinergic drugs are currently the therapy of choice to treat urgency and
urge incontinence. However, muscarinergic receptor blockers with adequate
selectivity for detrusor smooth muscle are not available. Also, in contrast to
the normal detrusor, the unstable detrusor neurotransmission seems to be at
least partially regulated by non-cholinergic (NANC) pathways. These factors may
explain the common side effects and the limited clinical efficacy of these
compounds. Specific modulation of intracellular second messenger pathways offers
the possibility of organ selective manipulation of tissue function, specifically
contraction and relaxation of smooth musculature. Because of their central role
in the intracellular regulation of smooth muscle tone phosphodiesterases (PDEs)
are an attractive pharmacological targets. The PDE 5 specific inhibitor
sildenafil (Viagra) has revolutionized the treatment of patients with erectile
dysfunction. Numerous other PDE inhibitors are currently under investigation for
the treatment of various disorders. We investigated the role of PDEs in human
detrusor smooth muscle. Our data demonstrate the presence of five PDE isoenzymes
in human detrusor and suggest, for the first time, that the cAMP pathway and the
calcium/calmodulin-stimulated PDE (PDE 1) are of functional importance in the
intracellular regulation in this tissue in vitro. In addition. initial clinical
data with the PDE 1 inhibitor vinpocetine in patients not responding to standard
anticholinergic therapy indicate a possible role for vinpocetine in the
treatment of urgency, urge incontinence and, possibly, low compliance bladder
and interstitial cystitis. The results of a larger randomized, double-blind,
placebo-controlled, multicenter trial with vinpocetine show a tendency in favor
of vinpocetine over placebo; however, statistically significant results were
documented for one parameter only. This might be due to the rather low dosage
chosen and the small sample size. Further studies are necessary and currently
underway to delineate the optimal dosage, indications and patient population.
Modulation of intracellular key enzymes effecting second messenger metabolism,
i.e. isoenzyme-selective PDE inhibition is a novel approach which possibly
avoids the limitations of anticholinergic therapy in patients with lower urinary
PMID: 11760783 [PubMed - in process]
Vinpocetine improves mental function through:
1. Improving the utilisation of glucose within the brain.
2. Improving the utilisation of oxygen within the brain.
3. Increasing circulation of blood to the brain.
4. Increasing production of ATP within the brain.
5. Increasing the turnover of the neurotransmitters norepinephrine and
6. Slowing deposit of lipofuscin pigment between brain nerve cells.
Vinpocetine is derived from vincamine an extract obtained from the periwinkle
plant. Although they have many similar effect Vinpocetine appears to have more
benefits and fewer adverse effects than vincamine. Adverse effects are rare, but
include hypotension, dry mouth, weakness, and tachycardia
Clinical studies have shown that it has a powerful stimulating effect on memory.
Vinpocetine as been shown to improve brain metabolism in the following ways. It
increases blood flow to the brain, and the rate of ATP production within the
brain (hence increasing the amount of energy available to the brain from ATP
action). Additionally the velocity of glucose and oxygen turnover within the
brain is expanded. As a result of the overall increase in activity of brain cell
metabolism the brain is able to retain a greater quantity of information and to
process that information faster.
Vinpocetine appears to combine many of the benefits of several other cognitive
enhancers. Clinical studies have found that in general Vinpocetine is better
than vincamine and in general is at least as good as Hydergine, xanthinol
nicotinate, meclophenoxate, niacin, and cyclandelate
Medically Vinpocetine is used in the treatment of cerebral circulatory disorders
including memory problems, stroke, aphasia, apraxia and dizziness as well as
sensorineural impairment of hearing. Additionally Vinpocetine is used to treat a
number of ophthalmologic disorders, with some improvement of visual acuity in
70% of the subjects.
Vinpocetine is particularly notable for its effect on short-term memory. In one
double-blind crossover study normal healthy volunteers demonstrated an
extraordinary improvement in short-term memory an hour after taking 40-mg of
Vinpocetine. The subjects showing a doubling of processing speed when receiving
Vinpocetine as against a placebo (Z, Subhan, I, Hindmarch,
"Psychopharmacological Effects of Vinpocetine in Normal Healthy Volunteers",
European Journal of Clinical Pharmacology 1985, Volume 28).
Adverse effects are rare, but include hypotension, dry mouth, weakness, and
tachycardia. Vinpocetine has no drug interactions, no toxicity, and is generally
Dosage: One or two 5 mg tablets per day
I take my Vinpocetine with my Idebenone.
1: Neuropharmacology 1989 Jun;28(6):569-73
Idebenone and vinpocetine augment long-term potentiation in hippocampal slices
in the guinea pig.
Ishihara K, Katsuki H, Sugimura M, Satoh M.
Department of Pharmacology, Faculty of Pharmaceutical Sciences, Kyoto
The effects of idebenone and vinpocetine which reportedly prevent impairment of
learning and memory were studied in vitro, on the long-term potentiation of the
population spike in the pyramidal layer of CA3 region of slices of hippocampus
in the guinea pig. Idebenone (10(-9) M-10(-6) M) or vinpocetine (10(-7) M-10(-6)
M) significantly augmented long-term potentiation in the mossy fibre-CA3
pyramidal cell system, without any significant changes in population spikes in
the absence of tetanic stimulation. These results suggest that both drugs have
direct actions on the hippocampal neurones to augment long-term potentiation at
fairly small concentrations. Further, when the two drugs were applied together,
the augmenting effects were additive.
PMID: 2569175 [PubMed - indexed for MEDLINE]